Am­gen and En­tera Bio call off oral drug de­liv­ery part­ner­ship af­ter four years

Am­gen and En­tera Bio are call­ing off a four-year re­search col­lab­o­ra­tion “out of mu­tu­al con­ve­nience,” En­tera re­vealed in its first-quar­ter re­sults.

The Jerusalem-based biotech is de­vel­op­ing new ways to ad­min­is­ter macro­mol­e­cules oral­ly, which is ex­pect­ed to al­low pa­tients to skip in­jec­tions.  When Am­gen put down $725,000 in ear­ly 2019 for ac­cess to the com­pa­ny’s oral drug de­liv­ery plat­form, the drug­mak­er planned to use the plat­form in an undis­closed pre­clin­i­cal large mol­e­cule pro­gram, with the promise of pay­ing En­tera up to $270 mil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.